In Other News

• GRAIL Presents Full Results from NHS-Galleri Trial at ASCO 2026

• Agentic AI Platform Supports Genomic Decision-Making in Oncology

• MCED Blood Test Reduces Stage IV Cancer Diagnoses in NHS Trial

• Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

• Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows

• AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes

• Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity

• Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

• Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak

• Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

• Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity

• Urine-Based Test Shows Promise for Autism Screening in Children

• Gut Microbiome Signatures Help Identify Risk of IBD Progression

• Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance

• Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps

• Werfen and Oxford Nanopore Collaborate on Transplant Assay Development

• Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance

• Urine-Based Test Shows Promise for Autism Screening in Children

• ClearNote Health to Present Pancreatic Cancer Blood Test Data at ASCO 2026

• ClearNote Health to Present Pancreatic Cancer Blood Test Data at ASCO 2026

• Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

• Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

• Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests